You are here
Due to the ongoing Coronavirus (COVID-19) pandemic, we ask for your patience regarding possible delays in the processing of new grant requests. The Global Medical Grants (GMG) team is currently providing grantees of current/ongoing studies and initiatives with information to ensure the health and safety of all involved in Pfizer-supported activities.
Pfizer Global Medical Grants (GMG) supports the global healthcare community’s independent quality improvement initiatives to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer’s medical and/or scientific strategies.
For all quality improvement grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, and conduct of the independent initiative supported by the grant. Pfizer must not be involved in any aspect of project development, nor the conduct or monitoring of the quality improvement program.
A quality improvement (QI) grant is a type of grant which consists of Pfizer funding to support independent projects for systematic and continuous actions that lead to measurable improvement in health care services and the health status of individuals and targeted patient groups and do not relate to a Pfizer asset. Quality improvement considers aspects of quality such as clinical competence, outcomes and process assessment, program evaluation, quality indicators, and quality assurance using methodologically rigorous protocols with an endpoint goal of readiness for application to practice.